Researchers believe they have solved a riddle that has challenged scientists for more than 70 years: how the brain chemical dopamine relates to schizophrenia, the often-devastating brain disorder characterized by delusional thinking, hallucinations and other forms of psychosis.
Through their exploration of the expression of genes in the caudate nucleus – a region of the brain linked to emotional decision-making – the researchers found physical evidence that neuronal cells are unable to precisely control levels of dopamine, and they also identified the genetic mechanism that controls the dopamine flow. Their findings were published in the journal Nature Neuroscience.
“Until now, scientists have been unable to decipher whether the dopamine link was a causative factor or solely a way to treat schizophrenia,” said a co-author of the study. “We have the first evidence that dopamine is a causative factor in schizophrenia.”
Dopamine, a type of neurotransmitter, acts as a chemical messenger that sends signals between neurons – nerve cells in the brain – to change their activity and behavior. Dopamine is the reward neurotransmitter that enables people to feel pleasure.
According to the National Institute of Mental Health, schizophrenia is 1 of the top 15 leading causes of disability worldwide, with psychotic symptoms such as hallucinations, delusions and disordered thinking, as well as reduced expression of emotions, reduced motivation to accomplish goals, difficulty in social relationships, motor impairment and cognitive impairment. Symptoms typically start in late adolescence or early adulthood, although cognitive impairment and unusual behaviors sometimes appear in childhood. Current treatments for schizophrenia include antipsychotic drugs which address the symptoms of pyschosis, but not the cause.
“One of the major side effects of the drugs used to treat schizophrenia is lack of pleasure and joy,” said one of the authors on the report. “In theory, if we could target the dopamine receptor specifically with drugs, that could be a new strategy for treatment that would not limit a patient’s joy as much.”
Scientists have known for decades that irregular levels of dopamine have some connection to psychosis and are a critical factor in schizophrenia, Alzheimer’s disease and other neuropsychiatric disorders. Drugs that increase dopamine in the brain, such as amphetamines, are known to cause psychosis. Drugs that treat psychosis do so by reducing dopamine activity.
These observations have inspired generations of scientists to try to understand whether – and how – an imbalance of dopamine actually relates to schizophrenia. Dopamine transmits information in the brain by interacting with proteins on the surface of brain cells, called dopamine receptors. By studying those receptors, scientists have come up with novel evidence confirming that dopamine is a causative factor for schizophrenia.
The investigators examined hundreds of post-mortem specimen brains from over 350 individuals, some with schizophrenia and others without psychiatric illness. They chose to focus on the caudate nucleus, a part of the brain that is critically important for learning how to make complex ideas and behaviors more automatic and intuitive, but also because it has the brain's richest supply of dopamine.
They also studied a region of the human genome that large international genetic studies have identified as being connected with the risk of schizophrenia. This region contains the genes for the protein receptors that respond to dopamine, which points to the dopamine-schizophrenia connection. But while genetic data suggest at most a role of dopamine receptors at risk for schizophrenia, the data are not conclusive and do not identify what the relationship actually is. The investigators went critically further in discovering the mechanisms that make dopamine receptors a risk factor.
The mechanism exists specifically in a subtype of the dopamine receptor, called the autoreceptor, which lies on the “male” side of the connection between neurons, the presynaptic terminal. This autoreceptor regulates how much dopamine is released from the presynaptic neuron. If autoreceptors are compromised, the flow of dopamine within the brain is poorly controlled, and too much dopamine flows for too long.
The investigators found that decreased expression of this autoreceptor in the brain explains the genetic evidence of risk for illness. This is consistent with the prevailing hypothesis that too much dopamine plays a role in psychosis, and strong evidence that the dopamine-schizophrenia riddle has at last been solved.
https://www.nature.com/articles/s41593-022-01182-7
Antipsychotic medication has an extensive influence on caudate gene expression
- 1,245 views
- Added
Latest News
Circadian rhythms can influ…
By newseditor
Posted 27 Apr
With hybrid brains, these m…
By newseditor
Posted 27 Apr
Blocking activation of NF-κ…
By newseditor
Posted 27 Apr
Vitamin D regulates microbi…
By newseditor
Posted 27 Apr
Role of alternative splicin…
By newseditor
Posted 27 Apr
Other Top Stories
A synaptic amplifier of hunger for regaining body weight in the hyp…
Read more
Men and women have different obesity drivers
Read more
On the origin of appetite
Read more
Brain cells that drive appetite in obesity
Read more
How increase in blood sugar affects Alzheimer's
Read more
Protocols
A programmable targeted pro…
By newseditor
Posted 23 Apr
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Publications
Single dose creatine improv…
By newseditor
Posted 27 Apr
Autonomous circadian rhythm…
By newseditor
Posted 27 Apr
Functional sensory circuits…
By newseditor
Posted 27 Apr
Positive selection CRISPR s…
By newseditor
Posted 27 Apr
Focal clusters of peri-syna…
By newseditor
Posted 27 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar